$151.14
-0.13[-0.09%]
At close: May 21
$151.14
0[0.00%]
After Hours: 4:57PM EDT
Johnson & Johnson
(NYSE:JNJ)Latest News for Johnson & Johnson Stock (NYSE:JNJ)
Johnson & Johnson Stock (NYSE: JNJ)
Categories: All
Tuesday, May 21, 2024
Monday, May 20, 2024
- Should You Invest in the Vanguard Health Care ETF?Zacks - 1 day ago
- Inquiry Into Johnson & Johnson's Competitor Dynamics In Pharmaceuticals IndustryBenzinga Insights - 1 day ago
- Johnson & Johnson Reports TREMFYA QUASAR Maintenance Study In UC Met Its Primary Endpoint And All Major Secondary Endpoints, Including Highly Statistically Significant Rates Of Endoscopic RemissionBenzinga Newsdesk - 1 day ago
Saturday, May 18, 2024
Thursday, May 16, 2024
- RBC Capital Reiterates Outperform on Johnson & Johnson, Maintains $175 Price TargetBenzinga Newsdesk - 5 days ago
- Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850MVandana Singh - 5 days ago
- Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma GameUpwallstreet - 5 days ago
- Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment for $850M Cash and Earnout ConsiderationBenzinga Newsdesk - 5 days ago
Wednesday, May 15, 2024
Tuesday, May 14, 2024
Monday, May 13, 2024
- Johnson & Johnson's Subsidiary Discontinues Some Megadyne Electrodes For Pediatric UseVandana Singh - May 13, 2024, 2:30PM
- Kenvue Announces Launch of Secondary Offering of $182.3M Shares by Selling StockholdersBenzinga Newsdesk - May 13, 2024, 6:48AM
- Kenvue Filed For Offering Of 182.3M Shares Of Common Stock By Selling ShareholdersCharles Gross - May 13, 2024, 6:43AM
Friday, May 10, 2024
Thursday, May 09, 2024
Tuesday, May 07, 2024
Monday, May 06, 2024
- Shockwave Medical Says Given The Proposed Acquisition Of Shockwave Medical By Johnson & Johnson, Shockwave Medical Is Withdrawing Its Full Year 2024 GuidanceBenzinga Newsdesk - May 6, 2024, 4:09PM
- Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest DataVandana Singh - May 6, 2024, 2:10PM
- Comparing Johnson & Johnson With Industry Competitors In Pharmaceuticals IndustryBenzinga Insights - May 6, 2024, 11:00AM
- On May 5, 2024, Johnson & Johnson Updated Results From Multi-Cohort Phase 1 Study Of The Safety And Efficacy; TAR-210 Results Show 90% Recurrence-Free Survival And 90% Complete Response In Patients With High-Risk And Intermediate-Risk Non-Muscle-Invasive Bladder Cancer, RespectivelyBenzinga Newsdesk - May 6, 2024, 10:27AM
- Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price TargetBenzinga Newsdesk - May 6, 2024, 9:59AM
Friday, May 03, 2024
- Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc ClaimsZacks - May 3, 2024, 4:00PM
- Johnson & Johnson Announces Phase 2 Data For ERLEADA Plus Androgen Deprivation Therapy Following Radical Prostatectomy In Patients With High-Risk Localized Prostate Cancer Show 100% Biochemical Free Recurrence Rate More Than Two Years Post-Surgery; Study Met Its Primary Endpoint; Safety Profile Of ERLEADA With ADT Was Consistent With Previous ReportsBenzinga Newsdesk - May 3, 2024, 12:23PM
- Johnson & Johnson Says TAR-200 Monotherapy Shows Greater Than 80% Complete Response Rate In Patients With High-Risk Non-Muscle-Invasive Bladder Cancer; New Data From Phase 2b Sunrise-1 Study Show Rapid Achievement Of Complete Response With 98% Achieving A CR Within 12 WeeksBenzinga Newsdesk - May 3, 2024, 11:20AM
Thursday, May 02, 2024
Wednesday, May 01, 2024
- Johnson & Johnson Wants To Deal With Talc Lawsuit Overhang, Proposes $6.5B Settlement PackageVandana Singh - May 1, 2024, 2:42PM
- Johnson & Johnson shares are trading higher after the company announced a Plan of Reorganization by its LLT Management subsidiary for the resolution of current and future ovarian cancer talc claims.Benzinga Newsdesk - May 1, 2024, 10:44AM
- Johnson & Johnson Disclosed A Proposed Plan Of Reorganization For The Comprehensive And Final Resolution Of All Current And Future Claims Related To Ovarian Cancer Arising From Cosmetic Talc Litigation Against It And Its Affiliates In USBenzinga Newsdesk - May 1, 2024, 6:39AM
Tuesday, April 30, 2024
Monday, April 29, 2024
- Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock TanksVandana Singh - Apr 29, 2024, 10:53AM
- J&J Says CHMP Recommends Conversion Of Conditional Marketing Authorization For Sirturo (Bedaquiline) Into Standard Marketing AuthorizationBenzinga Newsdesk - Apr 29, 2024, 10:19AM
- Johnson & Johnson Receives Positive CHMP Opinion Recommending Full Approval For Sirturo For Treatment Of Multidrug-Resistant TuberculosisBenzinga Newsdesk - Apr 29, 2024, 10:17AM
Wednesday, April 24, 2024
Tuesday, April 23, 2024
Monday, April 22, 2024
Friday, April 19, 2024
Thursday, April 18, 2024
Wednesday, April 17, 2024
- Johnson & Johnson Shares Hold Steady After Q1 Earnings, Analysts Optimistic About FutureVandana Singh - Apr 17, 2024, 3:37PM
- Johnson & Johnson Analysts Cut Their Forecasts After Q1 ResultsAvi Kapoor - Apr 17, 2024, 1:51PM
- RBC Capital Maintains Outperform on Johnson & Johnson, Lowers Price Target to $175Benzinga Newsdesk - Apr 17, 2024, 1:11PM
- Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price TargetBenzinga Newsdesk - Apr 17, 2024, 9:28AM
- Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For WednesdayAvi Kapoor - Apr 17, 2024, 8:21AM
- B of A Securities Maintains Neutral on Johnson & Johnson, Lowers Price Target to $170Benzinga Newsdesk - Apr 17, 2024, 6:33AM
Tuesday, April 16, 2024
- Stocks Grapple With Geopolitical Pressures, Gold Eyes $2,400, Bitcoin Falls Below $62,000: What's Driving Markets Tuesday?Piero Cingari - Apr 16, 2024, 1:28PM
- Johnson & Johnson shares are trading lower after the company issued 2024 guidance.Benzinga Newsdesk - Apr 16, 2024, 1:10PM
- Johnson & Johnson Shows Focus On Strengthening Its Business Upon Its Consumer Health Unit SpinoffUpwallstreet - Apr 16, 2024, 11:49AM
- Johnson & Johnson Q1 Earnings Top Wall Street Estimates On Strong Medical Devices Sales, Drugmaker Boosts Annual OutlookVandana Singh - Apr 16, 2024, 9:29AM